US Patent

US10532049 — Parenteral unit dosage form of dihydroergotamine

Formulation · Assigned to PHARMACEUTICAL INDUSTRIES Ltd · Expires 2039-02-26 · 13y remaining

Vulnerability score 55/100 Moderate — design-around opportunities exist

What this patent protects

This patent protects a parenteral unit dosage form of dihydroergotamine mesylate that has a specific pH to minimize impurities when stored under certain conditions.

USPTO Abstract

A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.

Drugs covered by this patent

Patent Metadata

Patent number
US10532049
Jurisdiction
US
Classification
Formulation
Expires
2039-02-26
Drug substance claim
No
Drug product claim
Yes
Assignee
PHARMACEUTICAL INDUSTRIES Ltd
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.